What Is Driving Global Circulating Tumor DNA (CtDNA) Methylation Market Growth in 2025: The Role of Rise In Cancer Prevalence Driving The Growth Of The Market Due To Increasing Demand For Early Detection And Personalized Treatment

Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

Circulating Tumor DNA (CtDNA) Methylation Market Size Growth Forecast: What to Expect by 2025?
In recent times, there has been a swift surge in the market size for circulating tumor DNA (CtDNA) methylation. This market, valued at $1.30 billion in 2024, is projected to grow to $1.48 billion in 2025, with a compound annual growth rate (CAGR) of 13.6%. The historic growth can be traced back to factors such as the escalating number of ctDNA methylation clinical trials, a surge in the adoption of precision medicine approaches, growing utility of biomarkers for prognosis, an increased number of published research endorsing the application of ctDNA methylation, and the rise in the implementation of high-end lab automation.

How Will the Circulating Tumor DNA (CtDNA) Methylation Market Size Evolve and Grow by 2029?
We are likely to witness a substantial surge in the size of the circulating tumor DNA (CtDNA) methylation market in the chronology to come, with prognostications pointing to a growth to $2.43 billion by the year 2029, representing a compound annual growth rate (CAGR) of 13.2%. The prediction of growth over the forecast period is attributable to various factors - the surge in point-of-care ctDNA testing solutions, the escalating adoption of telemedicine which promotes remote diagnostics, heightened global consciousness about epigenetic biomarkers, a rise in cross-industry collaborations and an upswing in partnerships between research entities and diagnostic firms. The upcoming trends that are expected to shape the market over the forecast period involve the inclusion of bioinformatics in methylation profiling, advancements in monitoring treatment response, innovations in mass screening programs, the integration of automated specimen processing systems, and novel progress in providing targeted therapy guidance.

View the full report here:
https://www.thebusinessresearchcompany.com/report/circulating-tumor-dna-ctdna-methylation-global-market-report

What Drivers Are Propelling the Growth of Circulating Tumor DNA (CtDNA) Methylation Market Forward?
The escalating incidence of cancer is projected to fuel the expansion of the circulating tumor DNA (ctDNA) methylation market in the future. The rise in cancer cases is attributed to an aging population and lifestyle-related risk factors such as unhealthy diet, smoking, and lack of physical activity that enhance the chance of genetic alterations and tumor formation. ctDNA methylation tests assist in early, non-invasive cancer detection, provide accurate disease progression monitoring, and facilitate personalized treatment decision-making, leading to timely and precise clinical interventions. As an example, the National Cancer Institute, a US government agency, estimated that in May 2024, cancer survivors' count in the United States would rise from 18.1 million in 2022 to 26 million by 2040. Hence, the escalating incidence of cancer is stimulating the growth of the ctDNA methylation market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=28167&type=smp

Which Emerging Trends Are Transforming the Circulating Tumor DNA (CtDNA) Methylation Market in 2025?
Companies leading the circulating tumor DNA (ctDNA) methylation market are prioritizing the creation of multi-cancer early detection (MCED) blood tests. These tests allow for the early, non-invasive detection of various cancer types by analyzing specific ctDNA methylation patterns. This patient outcome-enhancing method identifies distinctive methylation signatures, enabling swift intervention and assisting with accurate clinical decision making. For example, in September 2025, Exact Sciences Corporation, a US molecular diagnostics company, brought Cancerguard to the market. This MCED blood test uses ctDNA methylation analysis to detect unique methylation signatures across over 50 types of cancer. It provides non-invasive, extremely sensitive detection, giving clinicians valuable information and aiding in continuous monitoring and treatment decisions. This innovation is a significant move towards improving survival rates by facilitating early intervention in cancer treatment with a focus on precision.

What Are the Key Segments in the Circulating Tumor DNA (CtDNA) Methylation Market?
The circulating tumor dna (CtDNA) methylation market covered in this report is segmented as

1) By Product Type: Reagents And Kits, Instrumentations, Software And Bioinformatics Solutions, Services
2) By Technology: Polymerase Chain Reaction (PCR), Next-Generation Sequencing (NGS), Microarray, Other Technologies
3) By Sample Type: Blood Samples, Urine Samples, Saliva Samples, Tissue Samples, Other Samples
4) By Application: Oncology, Cardiovascular Diseases, Neurological Disorders, Infectious Diseases, Other Applications
5) By End-User: Hospitals And Clinics, Research Laboratories, Diagnostic Laboratories, Pharmaceutical And Biotechnology Companies, Academic Institutions

Subsegments:
1) By Reagents And Kits: Cell Free DNA Extraction Kits, Bisulfite Conversion Kits, Methylation Detection Kits, Library Preparation Kits, Targeted Enrichment Kits
2) By Instrumentations: Sequencers, Real Time Polymerase Chain Reaction Systems, Digital Polymerase Chain Reaction Systems, Microarray Scanners, Droplet Digital Polymerase Chain Reaction Systems
3) By Software And Bioinformatics Solutions: Data Analysis Software, Methylation Pattern Interpretation Software, Genomic Visualization Tools, Pipeline Automation Software, Clinical Reporting Software
4) By Services: Sample Processing Services, Sequencing Services, Bioinformatics Analysis Services, Clinical Trial Support Services, Consultation And Training Services

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=28167&type=smp

Who Are the Key Players Shaping the Circulating Tumor DNA (CtDNA) Methylation Market's Competitive Landscape?
Major companies operating in the circulating tumor dna (ctdna) methylation market are Thermo Fisher Scientific Inc., Agilent Technologies Inc., Illumina Inc., Sysmex Corporation, Bio-Rad Laboratories Inc., Exact Sciences Corporation, Qiagen N.V., Natera Inc., BGI Group, Guardant Health Inc., Invitae Corporation, Grail Inc., Genetron Holdings Limited, Buing Rock Biotech Limited, Zymo Research Corp, Agena Bioscience Inc., Phalanx Biotech Group Inc., Epigenomics Ag, EpigenDx Inc., Singlera Genomics Inc., Sampled.

What Geographic Markets Are Powering Growth in the Circulating Tumor DNA (CtDNA) Methylation Market?
North America was the largest region in the circulating tumor DNA (CtDNA) methylation market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in circulating tumor DNA (ctDNA) methylation report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=28167

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Saumya Sahey
Europe: +44 7882 955267,
Asia: +44 7882 955267 & +91 8897263534,
Americas: +1 310-496-7795
Email: saumyas@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.